Mikhail Blagosklonny is a scientist who has specialized in the study of cancer and aging. He is currently a professor and teaches Oncology at Roswell Park Cancer Institute. Mikhail studied at First Pavlov State Medical University and attained his M.D and, later on, Ph. D. in experimental medicine and cardiology. He worked at the New York Medical College as an Associate Professor before becoming a senior scientist at Ordway Research Institute. In 2009, Blagosklonny left Ordway and joined Roswell Park Cancer Institute. Follow Mikhail on Loop.
Study and Research
Mikhail Blagosklonny has had an interest in various studies. In his studies on cancer, he emphasized his research on targeted cancer therapies, which prevent healthy cells from being damaged by radioactive rays or chemotherapy. His other studies include the aging mechanism and anti-aging treatments, molecular and cellular biology, and clinical investigations. His research has focused on cell cycle, cellular senescence, signal transduction, and cancer therapeutics. He furthered the study of signal transduction pathways, which results to aging. In his signal transduction research, Blagosklonny discovered potential targets that decelerate age-related illnesses and aging process.
Mikhail postulated a theorem on the possible role of TOR in aging and cancer. He proposed that the rapamycin, which is a renowned drug for treating cancer, can be used as a treatment for extending the life of a person. Read more on Impact Journals
Publications and Editorial Works
Mikhail contributes widely to cell cycle, aging, and Oncotarget. He is also an assistant editor of biology and cancer therapy. Mikhail Blagosklonny is the founding and chief editor of International Journal of Cancer, Cancer Research, American Journal of Pathology, Cell Death, and Differentiation, and Autophagy. In 2010, Mikhail and Andrei Gudkov launched the Oncotarget, which is a weekly journal focusing on oncology research. Mikhail has written over 170 research articles.
His Role at Roswell Park Cancer Institute
Mikhail joined the institute in 2009. The staff received him with enthusiasm. At Roswell, experts share their ideas and the possible approaches that can help to curb cancer. Tissue-specific therapy and ways cancer can be prevented through slowing aging are some of the ideas that are worked on at the Institute. Given that this is Mikhail’s specialized field of study, he is considered as a great asset to the Institute.